Invitrogen said this week that RNAi pioneer Craig Mello has joined the company as a scientific advisor in the area of RNAi research.
According to Invitrogen, Mello will assist in the development and implementation of RNAi strategies at the company.
Mello is currently a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor’s degree in biochemistry from Brown University. He also recently joined the scientific advisory board of RNAi therapeutics developer CytRx.
“Our association with Dr. Mello opens doors to exciting new areas of discovery in RNAi,” Claude Benchimol, Invitrogen’s senior vice president of research and development, said in a statement. “By bringing his invaluable knowledge and experience in this area to our team, we hope to outpace the growing demand for cutting-edge methods to speed drug discovery research. We are honored to have him help with our development efforts.”